These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 33972663)

  • 1. Generative adversarial network for glioblastoma ensures morphologic variations and improves diagnostic model for isocitrate dehydrogenase mutant type.
    Park JE; Eun D; Kim HS; Lee DH; Jang RW; Kim N
    Sci Rep; 2021 May; 11(1):9912. PubMed ID: 33972663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differentiating between glioblastomas with and without isocitrate dehydrogenase gene mutation by findings on conventional magnetic resonance images.
    Shimizu T; Matsushima S; Fukasawa N; Akasaki Y; Mori R; Ojiri H
    J Clin Neurosci; 2020 Jun; 76():140-144. PubMed ID: 32291242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive role of magnetic resonance imaging in the distinction of isocitrate dehydrogenase (IDH) mutant grade 4 astrocytomas versus glioblastomas.
    Halefoglu AM; Camurcuoglu E; Tanik C; Kizilkaya O; Yilmaz A
    Acta Radiol; 2023 Jun; 64(6):2074-2086. PubMed ID: 37038636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isocitrate dehydrogenase (IDH) status prediction in histopathology images of gliomas using deep learning.
    Liu S; Shah Z; Sav A; Russo C; Berkovsky S; Qian Y; Coiera E; Di Ieva A
    Sci Rep; 2020 May; 10(1):7733. PubMed ID: 32382048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generative AI in glioma: Ensuring diversity in training image phenotypes to improve diagnostic performance for IDH mutation prediction.
    Moon HH; Jeong J; Park JE; Kim N; Choi C; Kim YH; Song SW; Hong CK; Kim JH; Kim HS
    Neuro Oncol; 2024 Jun; 26(6):1124-1135. PubMed ID: 38253989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluid attenuation in non-contrast-enhancing tumor (nCET): an MRI Marker for Isocitrate Dehydrogenase (IDH) mutation in Glioblastoma.
    Patel SH; Batchala PP; Muttikkal TJE; Ferrante SS; Patrie JT; Fadul CE; Schiff D; Lopes MB; Jain R
    J Neurooncol; 2021 May; 152(3):523-531. PubMed ID: 33661425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Refinement of response assessment in neuro-oncology (RANO) using non-enhancing lesion type and contrast enhancement evolution pattern in IDH wild-type glioblastomas.
    Moon HH; Kim HS; Park JE; Kim YH; Kim JH
    BMC Cancer; 2021 Jun; 21(1):654. PubMed ID: 34074252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IDH genotypes differentiation in glioblastomas using DWI and DSC-PWI in the enhancing and peri-enhancing region.
    Xing Z; Zhang H; She D; Lin Y; Zhou X; Zeng Z; Cao D
    Acta Radiol; 2019 Dec; 60(12):1663-1672. PubMed ID: 31084193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reproducible imaging-based prediction of molecular subtype and risk stratification of gliomas across different experience levels using a structured reporting system.
    Nam YK; Park JE; Park SY; Lee M; Kim M; Nam SJ; Kim HS
    Eur Radiol; 2021 Oct; 31(10):7374-7385. PubMed ID: 34374800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular landscape of IDH-mutant primary astrocytoma Grade IV/glioblastomas.
    Wong QH; Li KK; Wang WW; Malta TM; Noushmehr H; Grabovska Y; Jones C; Chan AK; Kwan JS; Huang QJ; Wong GC; Li WC; Liu XZ; Chen H; Chan DT; Mao Y; Zhang ZY; Shi ZF; Ng HK
    Mod Pathol; 2021 Jul; 34(7):1245-1260. PubMed ID: 33692446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gamma distribution model of diffusion MRI for evaluating the isocitrate dehydrogenase mutation status of glioblastomas.
    Takase H; Togao O; Kikuchi K; Hata N; Hatae R; Chikui T; Tokumori K; Kami Y; Kuga D; Sangatsuda Y; Mizoguchi M; Hiwatashi A; Ishigami K
    Br J Radiol; 2022 May; 95(1133):20210392. PubMed ID: 35138915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular habitat analysis based on dynamic susceptibility contrast perfusion MRI predicts IDH mutation status and prognosis in high-grade gliomas.
    Wu H; Tong H; Du X; Guo H; Ma Q; Zhang Y; Zhou X; Liu H; Wang S; Fang J; Zhang W
    Eur Radiol; 2020 Jun; 30(6):3254-3265. PubMed ID: 32078014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Machine learning reveals multimodal MRI patterns predictive of isocitrate dehydrogenase and 1p/19q status in diffuse low- and high-grade gliomas.
    Zhou H; Chang K; Bai HX; Xiao B; Su C; Bi WL; Zhang PJ; Senders JT; Vallières M; Kavouridis VK; Boaro A; Arnaout O; Yang L; Huang RY
    J Neurooncol; 2019 Apr; 142(2):299-307. PubMed ID: 30661193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IDH-wildtype glioblastomas and grade III/IV IDH-mutant gliomas show elevated tracer uptake in fibroblast activation protein-specific PET/CT.
    Röhrich M; Loktev A; Wefers AK; Altmann A; Paech D; Adeberg S; Windisch P; Hielscher T; Flechsig P; Floca R; Leitz D; Schuster JP; Huber PE; Debus J; von Deimling A; Lindner T; Haberkorn U
    Eur J Nucl Med Mol Imaging; 2019 Nov; 46(12):2569-2580. PubMed ID: 31388723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Importance of Age and Noncontrast-Enhancing Tumor as Biomarkers for Isocitrate Dehydrogenase-Mutant Glioblastoma: A Multicenter Study.
    Uetani H; Azuma M; Khant ZA; Watanabe Y; Kudo K; Kadota Y; Yokogami K; Takeshima H; Kuroda JI; Shinojima N; Hamasaki T; Mukasa A; Hirai T
    J Comput Assist Tomogr; 2023 Jul-Aug 01; 47(4):659-665. PubMed ID: 36877775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Less Invasive Phenotype Found in Isocitrate Dehydrogenase-mutated Glioblastomas than in Isocitrate Dehydrogenase Wild-Type Glioblastomas: A Diffusion-Tensor Imaging Study.
    Price SJ; Allinson K; Liu H; Boonzaier NR; Yan JL; Lupson VC; Larkin TJ
    Radiology; 2017 Apr; 283(1):215-221. PubMed ID: 27849434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Maximal Extent of Resection of Contrast-Enhanced and Non-Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed Glioblastoma.
    Molinaro AM; Hervey-Jumper S; Morshed RA; Young J; Han SJ; Chunduru P; Zhang Y; Phillips JJ; Shai A; Lafontaine M; Crane J; Chandra A; Flanigan P; Jahangiri A; Cioffi G; Ostrom Q; Anderson JE; Badve C; Barnholtz-Sloan J; Sloan AE; Erickson BJ; Decker PA; Kosel ML; LaChance D; Eckel-Passow J; Jenkins R; Villanueva-Meyer J; Rice T; Wrensch M; Wiencke JK; Oberheim Bush NA; Taylor J; Butowski N; Prados M; Clarke J; Chang S; Chang E; Aghi M; Theodosopoulos P; McDermott M; Berger MS
    JAMA Oncol; 2020 Apr; 6(4):495-503. PubMed ID: 32027343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. World Health Organization Grade II/III Glioma Molecular Status: Prediction by MRI Morphologic Features and Apparent Diffusion Coefficient.
    Maynard J; Okuchi S; Wastling S; Busaidi AA; Almossawi O; Mbatha W; Brandner S; Jaunmuktane Z; Koc AM; Mancini L; Jäger R; Thust S
    Radiology; 2020 Jul; 296(1):111-121. PubMed ID: 32315266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MRI Features May Predict Molecular Features of Glioblastoma in
    Park CJ; Han K; Kim H; Ahn SS; Choi D; Park YW; Chang JH; Kim SH; Cha S; Lee SK
    AJNR Am J Neuroradiol; 2021 Mar; 42(3):448-456. PubMed ID: 33509914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reliable diagnosis of IDH-mutant glioblastoma by 2-hydroxyglutarate detection: a study by 3-T magnetic resonance spectroscopy.
    Natsumeda M; Motohashi K; Igarashi H; Nozawa T; Abe H; Tsukamoto Y; Ogura R; Okada M; Kobayashi T; Aoki H; Takahashi H; Kakita A; Okamoto K; Nakada T; Fujii Y
    Neurosurg Rev; 2018 Apr; 41(2):641-647. PubMed ID: 28956184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.